Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vancomycin exposure in critically ill children undergoing high intensity continuous renal replacement therapy.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Restoration of lysosomal membrane integrity in cell models of Pompe disease depends on fatty acid synthase and its product palmitic acid.

Cellular & molecular biology letters·2026
Same author

Pediatric reference values of NT-proBNP and Galectin-3 based on a French cohort.

Clinica chimica acta; international journal of clinical chemistry·2024
Same author

Targeting TXNIP in endothelial progenitors mitigates IL-8-induced neutrophil recruitment under metabolic stress.

Stem cell research & therapy·2024
Same author

Fasting upregulates the monocarboxylate transporter MCT1 at the rat blood-brain barrier through PPAR δ activation.

Fluids and barriers of the CNS·2024
Same author

Biochemical Screening for Fetal Trisomy 21: Pathophysiology of Maternal Serum Markers and Involvement of the Placenta.

International journal of molecular sciences·2023

Related Experiment Video

Updated: May 22, 2026

Protocol to Create Chronic Wounds in Diabetic Mice
06:55

Protocol to Create Chronic Wounds in Diabetic Mice

Published on: September 25, 2019

Catalase polymorphisms and metabolic diseases.

Marylise Hebert-Schuster1, Emmanuelle E Fabre, Valérie Nivet-Antoine

  • 1Faculty of Pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France.

Current Opinion in Clinical Nutrition and Metabolic Care
|May 24, 2012
PubMed
Summary

Catalase gene polymorphisms are linked to metabolic diseases like diabetes and hypertension. Further research is needed to understand the exact mechanisms of these genetic variations in metabolism.

More Related Videos

Visualization of Mitochondrial Respiratory Function using Cytochrome C Oxidase / Succinate Dehydrogenase (COX/SDH) Double-labeling Histochemistry
06:53

Visualization of Mitochondrial Respiratory Function using Cytochrome C Oxidase / Succinate Dehydrogenase (COX/SDH) Double-labeling Histochemistry

Published on: November 23, 2011

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Experiment Videos

Last Updated: May 22, 2026

Protocol to Create Chronic Wounds in Diabetic Mice
06:55

Protocol to Create Chronic Wounds in Diabetic Mice

Published on: September 25, 2019

Visualization of Mitochondrial Respiratory Function using Cytochrome C Oxidase / Succinate Dehydrogenase (COX/SDH) Double-labeling Histochemistry
06:53

Visualization of Mitochondrial Respiratory Function using Cytochrome C Oxidase / Succinate Dehydrogenase (COX/SDH) Double-labeling Histochemistry

Published on: November 23, 2011

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

  • Genetics
  • Metabolic Diseases
  • Biochemistry

Background:

  • Catalase is an enzyme crucial for cellular defense against oxidative stress.
  • Metabolic diseases are a growing global health concern.
  • Genetic variations, or polymorphisms, in key enzymes like catalase may influence disease risk.

Purpose of the Study:

  • To review the current understanding of catalase gene polymorphisms and their association with metabolic diseases.
  • To explore the role of these polymorphisms in the development, management, and complications of metabolic disorders.

Main Methods:

  • Systematic review of existing scientific literature.
  • Analysis of studies investigating catalase single nucleotide polymorphisms (SNPs) and their correlation with metabolic parameters.
  • Synthesis of findings related to glucose metabolism, insulin resistance, hypertension, dyslipidemia, and bone metabolism.

Main Results:

  • Catalase polymorphisms are hypothesized to play a role in glucose disorders, including impaired glucose tolerance and insulin resistance.
  • Specific SNPs (-262C/T and -844A>G) are associated with hypertension susceptibility and onset.
  • Emerging evidence suggests a link between the -262C/T polymorphism and dyslipidemia, requiring further confirmation.
  • A role for catalase polymorphisms in bone metabolism has also been reported.

Conclusions:

  • Genetic variations in the catalase gene and its promoter are recognized as potential risk factors for metabolic diseases.
  • While associations are evident, the precise functional mechanisms by which these polymorphisms influence metabolic pathways remain largely unknown.
  • Further functional studies are essential to elucidate the direct impact of catalase polymorphisms on various metabolic processes.